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Abstract 
 
Langerhans cell histiocytosis (LCH) and Erdheim Chester Disease (ECD) are rare 
histiocytic disorders induced by somatic mutation of MAP kinase pathway genes.  
BRAFV600E mutation is the most common mutation in both conditions and also occurs 
in the hematopoietic neoplasm hairy cell leukemia (HCL).  It is not known if adult 
LCH or ECD arise from hematopoietic stem cells (HSC) nor which potential blood 
borne precursors lead to the formation of histiocytic lesions.  In this study, BRAF 
V600E allele-specific PCR was used to map the neoplastic clone in 20 adults with 
LCH ECD and HCL.  BRAFV600E was tracked to classical monocytes, non-classical 
monocytes and CD1c+ myeloid DCs in the blood and mutations were observed in 
HSCs and myeloid progenitors in the bone marrow of 4 patients.  The pattern of 
involvement of peripheral blood myeloid cells was indistinguishable between LCH 
and ECD, although the histiocytic disorders were distinct to HCL.  As reported in 
children, detection of BRAFV600E in peripheral blood of adults was a marker of active 
multi-system LCH (MS-LCH).  The healthy counterparts of myeloid cells affected by 
BRAF mutation had a range of differentiation potentials depending upon exogenous 
signals.  CD1c+ DCs acquired high langerin and CD1a with GM-CSF and TGFβ 
alone while CD14+ classical monocytes required additional notch ligation.  Both 
classical and non-classical monocytes, but not CD1c+ DCs made foamy 
macrophages easily in vitro with M-CSF and human serum (HS).  These studies are 
consistent with a hematopoietic origin and more than one immediate cellular 
precursor, in both LCH and ECD. 
 
248 words 
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Introduction 
Langerhans cell histiocytosis (LCH) and Erdheim Chester disease (ECD) are rare 
inflammatory myeloid neoplasms principally caused by mutations in the MEK-ERK 
signaling pathway, most commonly involving BRAF1–5.   LCH has a peak of 
incidence in childhood but an increasing number of adults are now also diagnosed, 
including some with a poor outcome due to MS-LCH6–8.  ECD, once considered a 
form of ‘non-Langerhans’ histiocytosis, appears to be a related condition by virtue of 
a common genetic landscape and the histological evidence of coexistent LCH and 
ECD in a proportion of adult patients9,10.   In contrast with LCH, ECD is rarely seen in 
children and predominantly affects older males11,12. 
 
In children with multi-system LCH (MS-LCH) caused by BRAFV600E, allele-specific 
PCR has been used to demonstrate mutant alleles in CD14+ and CD11c+ peripheral 
blood populations 5.  A hematopoietic origin was corroborated in two cases of MS-
LCH through expansion of hematopoietic clones in vitro5.  These studies support a 
model in which MS-LCH arises in the hematopoietic stem cell and is disseminated to 
the periphery by myeloid cells carrying somatic mutation13.  However, the identity of 
blood borne cells that give rise to peripheral tissue histiocytes remains open to 
further investigation, since more than one cell type carries BRAFV600E and myeloid 
lineages may have overlapping differentiation potentials. 
 
Human peripheral blood contains several subsets of myeloid mononuclear cells.  
Monocytes, comprise approximately 10% of mononuclear cells and may be divided 
into classical, non-classical and intermediate on the basis of CD14 and CD16 
expression14.  All human monocytes express CD11c. CD14+ classical monocytes 
are the most numerous and can be differentiated into macrophages and dendritic 
cells in vitro. Blood dendritic cells comprise 1-2% of mononuclear cells and are 
subdivided into CD123+ plasmacytoid DCs, and two subsets of CD11c+ myeloid 
DCs expressing CD1c+ and CD141+ 15.  CD1c+ DCs are the major population of 
myeloid DCs in blood and tissues.  They may express langerin in vivo16 and readily 
acquire a Langerhans cell-like phenotype in vitro17,18.   
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The differentiation potentials of monocytes and blood DCs overlap and monocyte-
derived DCs bear many markers in common with CD1c+ myeloid DCs19.  Monocytes 
have plasticity in many directions including DC and macrophage axes20,21 and may 
also express langerin in vitro under certain conditions22.  Thus multiple blood-derived 
populations have the potential to contribute to histiocytic lesions. 
 
The precursor populations of adults with LCH, ECD or LCH/ECD cross-over disease 
remain undefined.  It is not known whether MS-LCH in adults correlates with the 
presence of mutant alleles in peripheral blood or if it is possible to discern a similar 
risk stratification in patients with ECD.  NRAS mutation was detected in the CD14+ 
fraction of peripheral blood mononuclear cells in one patient 23 and ERK activation 
was reported in 1-3% of monocytes of an ECD cohort 24.  However, the involvement 
of other myeloid lineages has not been evaluated in ECD. 
 
Recent RNA-seq suggests that LCH lesions are enriched for dendritic cell gene 
transcripts while biopsies of ECD are enriched for myeloid precursor and 
macrophage gene expression 25.  It has been suggested that dendritic cell pathways 
of development may be involved in the generation of LCH, while monocyte-
macrophage differentiation could give rise to ECD.  Finally, BRAFV600E has been 
detected in hematopoietic stem cells of patients with hairy cell leukemia (HCL) and 
confirmed by xenografting 26.  There does not appear to be a clinical overlap 
between HCL and histiocytosis and the pathogenesis of these two different 
conditions from a common somatic mutation, is poorly understood.  HCL is therefore 
an interesting disease to evaluate in parallel and provides a useful control for the 
specificity of allele-mapping in histiocytosis.  
 
In this report, we have analyzed the distribution of BRAFV600E in the peripheral blood 
and bone marrow progenitor compartments of adults with MS-LCH, LCH/ECD cross-
over and ECD.  We sought to determine whether mutant alleles could be tracked to 
the hematopoietic stem cell, and whether there was a correlation between the 
architecture of the neoplastic clone and the clinical phenotype of histiocytosis.  We 
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also aimed to intersect these observations with studies to determine the potential of 
DC and monocyte lineages to generate LCH-like cells and foamy macrophages as in 
vitro surrogates of pathological histiocytes. 
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Methods 
Patient samples, lesional BRAFV600E testing and clinical data 
Blood, skin, bone marrow and surplus biopsy material was obtained from LCH and 
ECD patients referred to a local clinic with ethical approval from the Newcastle and 
North Tyneside Research Ethics Committee. Genomic DNA from formalin-fixed 
paraffin embedded LCH lesions was extracted using Promega Maxwell Tissue DNA 
Purification Kits (Promega; www.promega.co.uk) and the region flanking codon 600 
amplified by PCR.  Amplicons were purified and genotyped by primer extension for 
the c.1799T>A, p.Val600Glu (V600E) using the Sequenom iPlex protocol 
(Sequenom; www.sequenom.com).  The extension products were detected by 
MALDI-TOF Sequenom mass spectroscopy using a Sequenom Typer 4.0.  Disease 
activity was assessed by radiological examination including magnetic resonance 
imaging and positron emission tomography.   
Flow cytometry 
Absolute quantitation was performed using TruCount tubes on whole blood with a 
single step lyse no-wash protocol.  For more detailed analysis, whole blood was 
separated by density centrifugation into mononuclear and red cell/neutrophil 
fractions.  The red cell pellet was subsequently used for extraction of neutrophil 
DNA.  Flow cytometry was performed on an LSRII or LSR Fortessa cytometer from 
Becton Dickinson (BD; www.bd.com) and data analyzed with FlowJo (Treestar). 
Fluorescence activated cell sorting (FACS) was performed using a BD FACS Aria.  
Sorted cells were collected into microfuge tubes containing RPMI with 10% fetal calf 
serum.  
 
Antibodies were from BD unless stated otherwise and are denoted as: antigen 
fluorochrome (clone). CD1a BV421 (HI149; Biolegend; www.biolegend.com); CD1c 
APC (AD5-8E7; Miltenyi Biotec; www.miltenyibiotec.com); CD3 FITC (SK7); CD3 
V500 (UCHT1); CD7 FITC (4H9); CD10 PE-TR (B-Ly6; Beckman Coulter; 
www.beckmancoulter.com); CD11c A700 (B-ly6); CD14 APCCy7 (MΦP9); CD14 
FITC (M5E2); CD16 FITC (NKP15/Leu-11a); CD16 PeCy7 (B73.1); CD19 FITC 
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(4G7); CD19 PECy7 (SJ25C1); CD20 FITC (L27); CD34 PE (8G12); CD34 FITC 
(8G12); CD34 APC (581); CD38 PECy7 (HB7); CD45 V450 (2D1); CD45 APCCy7 
(2D1); CD45RA BV510 (HI100; Biolegend); CD56 FITC (NCAM16.2); CD90 
PerCPCY5.5 (5E10; Biolegend); CD123 PerCPCY5.5 (7G3); CD123 PE (9F5); 
CD207 PE (DCGM4; Beckman Coulter); HLA-DR V500 (L243/G46-6); HLA-DR A700 
(L243/G46-6). 
BRAFV600E allele-specific PCR 
Genomic DNA from sorted blood cells, bone marrow cells control cell lines or cell-
free sources was extracted using Qiagen micro-kits (Qiagen; www.qiagen.com) 
BRAF mutation and reference qPCR was performed with competitive allele-specific 
Taqman® mutation detection assays: Mutation Allele Assay: BRAF_476_mu 
4465804 Hs00000111_mu; Gene Reference Assay - BRAF_rf - 4465807 
Hs00000172_rf, according to the manufacturer’s instructions (Life Technologies; 
www.lifetechnologies.com). A standard curve was derived from 6 serial dilutions of 
genomic DNA from BRAFV600E melanoma cell line A375 and EBV-transformed LCLs. 
0%, 0.1% and 10% V600E mutation controls were performed with every run. The 
percentage of BRAFV600E mutation was determined from the dCT (CTreference-
CTmutant) using the standard curve. Graphs were plotted with Prism Version 5.0 
(GraphPad Software, Inc.).  
In vitro differentiation 
Aliquots of 10,000 sorted cells from healthy controls were cultured in RPMI 1640 with 
10% fetal bovine serum or 5% human serum in 100μl in 96-well plates Supplements 
were added at: GM-CSF 50 ng/μl; TGFβ, 10 ng/μl; M-CSF 50 ng/μl. Cultures were 
maintained for 3 days before analysis by flow cytometry.  For phase contrast 
microscopy, cells were cultured in Thermo Scientific Nunc chamber slides System 
for 7 days, washed gently and fixed with 1% paraformaldehyde in PBS and images 
acquired with Carl Zeiss Axioplan 2 x40 objective and Carl Zeiss Axiovision software 
release 4.8 
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Statistical methods 
Mann Whitney tests, t-tests and Fisher’s exact test were performed using GraphPad 
Prism 5.0 software. 
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Results 
Fifty-two adults with histiocytosis and 4 with HCL were recruited from a local clinic 
and collaborating centers (Figure 1).  Twenty with histiocytosis and all with HCL had 
confirmed BRAFV600E lesions.  Three additional children with BRAFV600E -mutated 
LCH were included in some analyses for comparison.  Further clinical details are 
given in Supplementary Table 1.  
 
Detection of BRAFV600E was performed using an allele-specific PCR and was 
sensitive to 0.01% with a quantitative range to 0.1% (Figure 2A). BRAFV600E alleles 
were detectable in DNA isolated from PBMC of patients with active multi-system 
LCH with or without co-existent ECD (LCH/ECD cross-over), but were only present 
in one patient with SS LCH (Figure 2B).  ECD is not conventionally classified into 
SS or MS. Nearly all cases involved multiple systems. There was no clear correlation 
between clinical features and BRAFV600E detection the PBMC (see Supplementary 
Table 1 for details) 
 
A simple linear correlation was observed between the frequency of mutant allele 
detection in PBMC vs. cell-free plasma DNA, with approximately half-log greater 
sensitivity for detection in cellular DNA (Figure 2C).  In order to exclude the uptake 
of free DNA into the cell-associated pool by phagocytosis or macropinocytosis,  
purified BRAFV600E mutated DNA from A375 cells was incubated with whole blood of 
healthy controls (Figure 2Di) and sorted cell fractions were cultured with medium 
containing 20% serum form a patient with HCL (Figure 2Dii).  Cellular and cell-free 
DNA was then recovered and subjected to PCR.  Mutated BRAF alleles were only 
recovered from the cell-free fraction, but not the cellular DNA, indicating that uptake 
of exogenous DNA did not account for cell-associated BRAFV600E.  With patient 
serum, cell cultures not only remained negative but diluted or degraded the cell-free 
signal. 
 
The pattern of mononuclear cells observed by flow was analyzable by conventional 
gating and no atypical populations were detected  (Supplementary Figure 1).  
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Neither langerin+CD1a+ LCH-like cells nor CD103+ CD11c+ hairy cells were 
detectable in any of the histiocytosis patients (Supplementary Figure 1).  Absolute 
counting of PBMC from patients with histiocytosis revealed monocytosis and 
increased numbers of total CD11c+ and CD11c+CD1c- myeloid cells 
(Supplementary Figure 1,2).   There were no detectable differences between BRAF 
mutated and WT disease although power to detect subgroup differences was limited.  
No cytological atypia was observed among monocytes and DC subsets 
(Supplementary Figure 3). 
 
In order to map the distribution of mutant alleles, PBMC from 9/11 patients with 
circulating BRAFV600E and 2 children with MS-LCH, were fractionated into four 
quadrants according to the expression of HLA-DR and lineage (CD3, CD19, CD20 
and CD56).  The gates were completely apposed in order to account for all mutant 
alleles present in PBMC and to exclude the inadvertent loss of signal to an 
uncharacterized disease-related population.  
 
In contrast to patients with HCL, in which BRAFV600E was largely confined to the 
HLA-DR+ lineage+ quadrant containing hairy cells, mutation in patients with 
histiocytosis was highly enriched in the HLA-DR+ lineage- quadrant containing 
monocytes and DCs (Figure 3A). Some overspill into adjacent quadrants was 
observed, owing to the close gating.  For example, in histiocytosis patients, positivity 
appeared in the HLA-DR- lineage- quadrant.  This was further studied in case A2951 
and found to be associated with CD14+ monocytes and CD11c+ myeloid precursors 
expressing low HLA-DR at the top of the double negative gate (data not shown).  
 
The mononuclear compartment was further fractionated to explore the distribution of 
mutant alleles at higher resolution (Supplementary Figure 1, 2; Figure 3B). As 
expected, BRAFV600E was localized to hairy cells with a low level of alleles detectable 
in phenotypically normal B and NK cells but none in the remaining monocytes and 
myeloid cells.  In contrast, the majority of alleles in patients with histiocytosis were 
found in CD14+ classical monocytes, CD16+ non-classical monocytes and CD11c+ 
CD1c+ myeloid DCs.  Plasmacytoid DCs harbored some alleles in LCH patients and 
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in one case BRAFV600E was also detectable at a low level in B and T cells.  The 
distribution of alleles did not vary significantly between LCH, ECD and patients with 
LCH/ECD.  In addition to these compartments, we studied CD14+CD16+ 
intermediate monocytes and CD11c+CD1c- myeloid cells in a subset of patients (see 
Supplementary Figures 1,2,4 for details).  These did not differ significantly from the 
allele level in CD14+ classical monocytes and CD1c+ myeloid DC, respectively. 
 
BRAFV600E mutation was previously reported in children with MS-LCH, using a more 
simple gating strategy to obtain CD14+ and CD11c+ myeloid cells 5. CD11c+ 
myeloid cells comprise multiple fractions including CD1c+ myeloid DCs, CD16+ non-
classical monocytes and CD11c+CD1c- cells which were analyzed separately here.  
The relationship between these populations is summarized in Supplementary 
Figure 4. 
 
In order to probe the hematopoietic origin of LCH and ECD, bone marrow was 
analyzed from 2 patients with multi-system LCH and 2 with ECD.  One ECD patient 
(A7344) had mutated NRAS rather than BRAF and was previously reported to have 
a high level of NRAS mutation in CD14+peripheral blood monocytes (A7344) 23.  A 
commonly used schema for immunophenotyping (Supplementary Figure 5), 
revealed that the common myeloid progenitor (CMP) and granulocyte-macrophage 
progenitor (GMP) compartments were relatively expanded (Figure 4A).   BRAFV600E 
was detectable in CD90+ CD45RA- CD38low hematopoietic stem cells, CD38high 
CD45RA- CMP and CD45RA+ GMP (Figure 4B).  The mutant allele was present at 
<1% in HSCs and was most enriched in the CMP fraction.  Mature histiocytes arising 
from the mutated clone were rigorously excluded in this analysis  (Supplementary 
Figure 5).   A pediatric patient included for comparison showed a similar distribution 
of alleles.  The NRAS mutated patient was quantified by peak height on Sanger 
sequencing at 21-63% in myeloid precursor fractions.  Progenitor cells from this 
patient were demonstrated to engraft in immunodeficient mice, in the accompanying 
paper. 
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These results suggest that LCH and ECD arise in the hematopoietic stem cell and 
that are transmitted to peripheral tissues by blood-borne myeloid cells.  However, 
there was no obvious disease-specific bias in the distribution of mutant alleles 
among myeloid cells, that might correlate phenotypic differences between LCH and 
ECD.  We therefore evaluated the potential of each myeloid fraction to give rise to 
the characteristic cells of LCH and ECD lesions through in vitro differentiation of 
sorted fractions from healthy controls. 
 
It has previously been demonstrated that monocytes and CD1c+ DCs can express 
langerin in vitro under different conditions but only cells with high langerin and CD1a 
contain Birbeck granules 17,18,22,27,28.  Previous reports are discordant and have not 
examined monocytes and DCs from peripheral blood and compared their 
differentiation capacity in the same platform.  We therefore tested the development 
of an LC-like phenotype by blood monocytes and CD1c+ DCs using conditions that 
had been previously described in either monocytes or DCs17,18,22,27,28: soluble factors 
GM-CSF and TGFβ and the notch ligands DLL1 and DLL4, expressed on mouse 
OP9 cells.   In order to study the potential to develop foamy macrophage 
morphology, we used M-CSF with 5% human serum.  
 
As shown previously, CD1c+ DCs attained high langerin expression with GM-CSF 
and TGF-β alone. Soluble factors GM-CSF and TGF-β, were not sufficient to induce 
high langerin in CD14+ monocytes but this potential was revealed by co-culture with 
notch ligands DLL1 and DLL4.  CD16+ monocytes did not express high langerin 
under any conditions but notch ligation also further enhanced the expression of 
langerin by  CD1c+ DCs in response to soluble factors (Figure 5 and 
Supplementary Figure 6). In macrophage differentiation conditions, CD1c+ DCs 
were unable to form foam cells while both monocyte subsets developed this 
phenotype.  A summary of the distribution of BRAF alleles and differentiation 
potential of myeloid lineage affected is shown in Table 1.  
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Discussion 
Prior to the discovery of BRAFV600E there was accumulating evidence that both LCH 
and ECD were clonal proliferations of histiocytes, including a remarkable insight by 
Chetritt and colleagues that ECD was the ‘macrophage counterpart to LCH’ 29,30.  
Here we have exploited the recurrent BRAFV600E mutation to map the neoplastic 
clones of LCH and ECD.  The results further reinforce the concept that LCH and 
ECD are closely related hematopoietic neoplasms, regardless of their distinctive 
pathological features 31.   
 
A high resolution analysis of myeloid cells demonstrated the highest frequency of 
mutant alleles in CD14+ classical monocytes, CD16+ non-classical monocytes and 
CD1c+ myeloid DCs.  Unexpectedly, the non-classical monocyte is a reservoir of 
BRAF mutation and accounts for a proportion of the signal previously tracked to 
CD11c+ myeloid cells5.  We also mapped BRAF mutation to cells defined by 
phenotype as HSCs in LCH, ECD and HCL.  BRAFV600E has previously been 
reported in HSCs of children with MS-LCH 5 and patients with HCL 26 and it remains 
unclear how the same mutation present in HSCs generates such unrelated 
pathologies. Although there is a documented overlap between LCH and ECD 9,10 
HCL is unrelated in incidence and we did not observe HCL leukocytes in any patient 
with histiocytosis. 
 
The initial cell sorting approach adopted apposed gating of the HLA-DR vs. lineage 
plot of total PBMC in order to account for all the mutated alleles present in PBMC 
DNA (neutrophils were consistently negative).  Although we localized most of the 
BRAFV600E alleles in peripheral blood to the HLA-DR+ lineage- compartment of both 
LCH and ECD, some overspill was observed into the HLA-DR- lineage- cells, owing 
to this strategy.  While a proportion of this signal was contained in HLA-DRlo CD14+ 
monocytes, CD11c+ CD1c- myeloid progenitors that may generate macrophages 
and are also found in this region.  In particular, ECD patients frequently have 
expanded myelopoiesis with an element of left-shift that mobilizes these cells into the 
peripheral compartment; thus we cannot exclude a contribution of more primitive 
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myeloid precursors to the lesions of ECD.  Notably, recent gene expression studies 
described enrichment for myeloid progenitor signatures in ECD lesions 25. 
 
There is significant interest in cell-free DNA as a marker of neoplasia and this is also 
detectable in histiocytosis 32.  In our hands, plasma cell-free BRAFV600E was 
approximately half-log lower in abundance than cell-associated alleles.  We 
considered the possibility that exogenous DNA might account for the mutant alleles 
found in PBMC, especially as the signal was localized to monocytes with phagocytic 
activity.  However, exposure of healthy control blood to BRAF mutated genomic DNA 
did not result in a cell-associated signal.  Furthermore, the lack of mutated alleles in 
neutrophils but the localization of mutation to non-phagocytic CD34+ progenitor 
cells, argue against phagocytic uptake of exogenous DNA as a significant source of 
artifact. 
 
Total RNA profiling reveals a strong DC-related and macrophage-related signature in 
LCH and ECD, respectively 25.  However, there was no bias in the distribution of 
mutated alleles to suggest that the phenotypic differences of LCH and ECD lesions 
are determined by the myeloid lineages harboring BRAF mutation.  This may not be 
surprising given the relatively high incidence of overlap cases now documented 9,10.  
Many alternatives may explain the variation between LCH and ECD, such as genetic 
background, age-related myeloid hematopoietic bias 33, additional somatic mutation 
34
 or extrinsic inflammatory signals arising independently in the local tissue 
environment.  The difference in median age of onset between LCH and ECD is 
consistent with an influence of age-related myeloid bias or clonal hematopoiesis.  
From a pathological perspective, the occurrence of LCH and ECD together in a 
single lesion, suggests a cell-intrinsic mechanism 10.  However, in cases where an 
overlap syndrome occurs with distinct and characteristic anatomical distributions of 
each disease, the tissue environment may direct either LCH or ECD-like pathology, 
through extrinsic signals.   In keeping with previous reports of expanded 
myelopoiesis in MS-LCH35, we observed an increase in blood myeloid cells and BM 
myeloid progenitors in adult LCH and ECD. 
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The differentiation of myeloid cells in response to cytokine and notch-mediated 
signaling showed that more than one precursor has the potential to form cells with 
characteristic properties of LCH and ECD histiocytes.  The critical role of notch 
signaling in permitting LC development from monocytes was first reported in 
response to delta-like protein 1 (DLL1) 22.  Without this signal, CD14+ classical 
monocytes only express low langerin and are unable to form Langerinhigh CD1a+ 
cells containing Birbeck granules, in response to GM-CSF and TGFβ.  In contrast, 
CD1c+ DCs spontaneously express langerin in vivo 16 and rapidly acquire LC-like 
properties when exposed to GM-CSF and TGFβ 17,18.  In vitro differentiation 
experiments presented here clearly show that two pathways may generate 
langerinhigh cells and that delta-like protein 4 (DLL4) provides a more potent signal 
for monocytes than DLL1.  Recent molecular studies have shown that DLL1 induces 
LC development in monocytes by down-regulating KLF and de-pressing RUNX328.  
Elevated GM-CSF, M-CSF and FLT3 ligand have been reported in the serum of 
patients with LCH, consistent with a pathological role of these cytokines35,36.  Intrinsic 
notch signaling was previously suggested as a key mechanism promoting LCH 
pathogenesis, through expression of Jagged 2 by lesional histiocytes 27. Taken 
together, these observations do not support a simple dichotomous model that LCH 
arises from the DC pathway and ECD from the monocyte-macrophage pathway of 
myeloid cell development.  Classical monocytes appear able to contribute to 
histiocytes of both disorders, depending upon the signals they receive.  CD1c+ DCs, 
on the other hand, were unable to form foamy macrophages when exposed to 
strongly macrophage promoting conditions of M-CSF and lipid-containing human 
serum.  Both classical and non-classical monocytes rapidly differentiated into typical 
foam cells under these conditions.  CD16+ non-classical monocytes are likely to be 
heterogeneous and have also been characterized as DC-like 37,38.  It is possible that 
a subpopulation formed the macrophages observed in culture as the final density 
was lower than for equivalent numbers of CD14+ monocytes.  Given the high 
proportion of BRAF mutated alleles in CD16+ monocytes, they may contribute to 
histiocytes in the lesions of ECD, although they are reported to be unable to form 
giant cells.  The occurrence of mutated alleles in monocytes also presents the 
possibility that macrophages in LCH lesions arise from the neoplastic clone.  
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Previous studies show that M-CSF, one of the factors used to differentiate foam 
cells, is significantly increased in MS-LCH35 
 
An important caveat of the in vitro differentiation experiment is that healthy control 
cells without BRAF mutation were used.  In the absence of a surface antigen that 
can distinguish mutated and unmutated progeny, this analysis cannot be performed 
with enriched BRAF-mutated cells isolated from patients.  The presence of mutation 
may not matter since ERK activation is a consequence of many of the stimuli used in 
vitro.  However, it remains hypothetically possible that intrinsic BRAF activation has 
other unanticipated effects. 
 
The finding that BRAF mutated PBMC are detected at higher level in MS-LCH has 
potential utility as an indicator of clinical risk and response to therapy, as suggested 
in children5.  Our conclusion in adults is based on only 8 patients and should be 
expanded to a larger cohort, ideally.  The sensitivity of detection using allele-specific 
PCR is critical as less sensitive techniques failed to find BRAF mutation in peripheral 
blood or bone marrow fractions previously 2,4.  BRAFV600E was detected in PBMC of 
a subset of ECD patients and it remains to be determined, using a large group, 
whether  this segregates with disease risk in ECD. 
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Table legend 
Table 1 
Table summarizing BRAFV600E mutant allele frequency among blood monocytes and 
myeloid DCs (data from Figure 3) and the potential of wild-type cells to form langerin 
high LCH-like cells or foamy macrophages in vitro.  Frequency of langerin high 
indicated as follows:   - <10%; + 10-25%; ++ 26-35% and +++ >35 % 
 
Figure legends 
Figure 1.  Patients 
Summary of adult patients included in the study.  WT wild-type; NT not tested; LCH 
Langerhans cell histiocytosis; ECD Erdheim Chester Disease;  HCL Hairy Cell 
Leukemia.  Asterisks indicate the number of patients with BRAFV600E detectable in 
PBMC.  The BRAF wild type ECD group includes one patient with RAS mutation  
 
Figure 2.  Detection of BRAFV600E alleles 
A. A standard curve constructed using DNA purified from a dilution series of 
BRAFV600E positive melanoma cell line A375 into wild-type Epstein-Barr virus 
(EBV) transformed lymphoblastoid cell line. The quantitative limit detection was 
0.1%; the  absolute limit of detection was 0.01% (POQR). 
 
B. BRAFV600E allele frequency in bulk PBMC in cases of lesion BRAFV600E+ LCH, 
LCH/ECD and ECD.  Contingency of positive PBMC upon multisystem LCH 
tested by Fisher’s exact test.  
 
C. Correlation between mutated allele burden in cell-free plasma and PBMC DNA in 
LCH, ECD and HCL. 
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D. I. Test of exogenous free DNA uptake by PBMC. BRAF mutated DNA (derived 
from melanoma cell line A375 was spiked into whole blood for 24 hours at room 
temperature.  Plasma and PBMC were isolated by density centrifugation. DNA 
was extracted from both fractions and subjected to allele-specific PCR.  
II. Test of exogenous free DNA uptake by sorted cells incubated at 37oC for 24 
hours in medium supplemented with 20% human serum from a patient with hairy 
cell leukemia. DNA from supernatants and cell pellets, as indicated, was 
subjected to allele-specific PCR. 
Figure 3.  Allele-specific PCR of BRAFV600E in PBMC 
A. The distribution BRAFV600E in PBMC sorted into quadrants as shown according to 
expression of HLA-DR and lineage.  Pie charts summarize the distribution of 
mutant alleles in HCL, LCH and ECD. The area of each quadrant in the pie is 
proportional to the total number of mutant alleles in that quadrant (i.e the 
percentage positivity of the quadrant multiplied by the number of cells in the 
quadrant).  All patients had active disease at the time of sampling. Two children 
with LCH included for comparison, are indicated.  *Indicates the threshold of 
detection for a negative result where cell numbers were limiting.   
 
B. The distribution BRAFV600E among peripheral blood cells showing the % mutated 
alleles detected.  NT = not tested owing to lack of or insufficient material. * Child 
with MS-LCH shown for comparison.  All patients had active disease at the time 
of sampling.  Italics indicate those who had received prior treatment. 
 
Figure 4.  Mononuclear profile and BRAF allele frequency in CD34+ BM 
progenitors 
A. Relative proportions of progenitor fractions among CD34+ bone marrow 
mononuclear cell compared with healthy controls (n=21), expressed as 
percentage of total live cells. Error bars depict 95% confidence intervals of 
healthy controls. Populations: HSC: Hematopoietic stem cells; LMPP: lymphoid-
primed multi-potent progenitors; B/NK: B/NK cell progenitors; CMP: common 
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myeloid progenitors; GMP: granulocyte/macrophage progenitors.  MPP: 
multipotent progenitor.  
B. The distribution BRAFV600E among CD34+ bone marrow progenitors.  BM aspirate 
was obtained in parallel with the peripheral blood shown previously.  NT = not 
tested owing to insufficient number of cells.  
 
Figure 5.  in vitro differentiation potential of monocytes and myeloid DCs  
A. Sorted CD14+ monocytes, CD16+ monocytes and CD1c+ myeloid DCs from 
healthy controls cultured for 3 days in conditions as shown.  Langerin high 
CD1a+ gates depicted contain LCH-like cells with Birbeck granules.   Notch 
ligands DLL1 And DLL4 were presented on transfected mouse OP9 cells.  
Representative data of 5 independent experiments. 
 
B. Sorted CD14+ monocytes, CD16+ monocytes and CD1c+ myeloid DCs from 
healthy controls cultured for 7 days with M-CSF and 5% human serum (HS) to 
reveal potential to differentiate into foamy macrophages.  Representative phase 
contrast images of 5 independent experiments.. 
 
Figure 6.  Potential precursor pathways in MS-LCH and ECD 
Schema summarizing potential precursor pathways in MS-LCH and ECD based on 
the distribution of BRAFV600E alleles in peripheral blood and the differentiation 
potentials of healthy control cells in vitro.  A minority of cells (filled) in the BM and 
blood contain BRAF mutation.  The principal observation is that <1% clonal 
haematopoiesis gives rise to <3% mutated blood precursors that appear to be 
strongly selected for in peripheral tissue environments, resulting in lesional histiocyte 
mutation levels of up to 100%.  Lesions potentially consist of more than one 
precursor as indicated by blue for CD1c+ DC, red for classical monocyte and brown 
for non-classical monocytes.  The depiction of lesion composition is conjectural and 
not based upon experimental observation.  Furthermore, additional contributions 
from other more primitive myeloid progenitors, cannot be excluded at present.  
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Abbreviations: HCL: hairy cell leukemia; LCH: Langerhans cell histiocytosis; ECD: 
Erdheim Chester disease 
 
Table 1 
 
 
CD14 CD16 CD1c 
% BRAF
V600E
 
   
median 0.38 1.36 0.2 
range 0-18 0-45 0-8 
    
Langerin+ potential 
   
GM-CSF +TGFβ - - ++ 
+DLL1 + - +++ 
+DLL4 +++ - +++ 
    
Foamy mac potential +++ +++ - 
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